Executives Talk Real-World Data and Drug Development

In a recent virtual roundtable, clinical research executives spoke about the growing implementation of real-world data (RWD) in research and drug development. A key use, voiced by Alira Health’s CEO Gabriele Brambilla, is in external control arms, which let researchers use existing RWD to serve as a control group for clinical trials.

According to Brambilla, “And the second one, which is very exciting—but not a lot of people are talking about—is all the new software and algorithms coming out for biosimulation. What we use to train these systems and algorithms is RWD. It is electronic health record (EHR) data. And that allows the development of systems and algorithms that can help develop clinical trials or biosimulation for PK/PD (pharmacokinetics/pharmacodynamics). So that’s exciting, and I see more and more of that in the market right now.”

To read more, click here.

(Source: Applied Clinical Trials, May 17^th, 2023)